Retatrutide, a groundbreaking dual-acting glucose-regulated incretin mimetic, represents a significant advance in peptide medicines for the handling of type 2 diabetic conditions and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor agonist, offering a